Chunbing Lyu
Overview
Explore the profile of Chunbing Lyu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
103
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tamabuchi E, Fujimura T, Lyu C, Aiba S
Dermatol Ther
. 2021 Apr;
34(4):e14961.
PMID: 33913225
No abstract available.
2.
Ohuchi K, Fujimura T, Lyu C, Amagai R, Muto Y, Aiba S
J Dermatol
. 2020 Dec;
48(3):353-359.
PMID: 33264451
CXCL13 recruits CXCR5 follicular helper T (Tfh) cells in inflammatory lesions to develop secondary lymphoid organs. Tfh cells activate B cells to produce antibodies during humoral immune responses. Indeed, as...
3.
Sato Y, Fujimura T, Hidaka T, Lyu C, Tanita K, Matsushita S, et al.
Front Immunol
. 2020 Nov;
11:534323.
PMID: 33178182
Aryl hydrocarbon receptor (AhR) provides a deeper insight into the pathogenesis of cutaneous squamous cell carcinoma (cSCC). AhR ligands, such as 6-formylindolo[3,2-b] carbazole (FICZ), and 7,12-Dimethylbenz[a]anthracene (DMBA), constitute major substrates...
4.
Sasaki R, Fujimura T, Lyu C, Aiba S
J Dermatol
. 2020 Aug;
47(12):1436-1438.
PMID: 32860247
Enfortumab vedotin (EV) is a novel, fully humanized monoclonal antibody-drug conjugate composed of an anti-Nectin-4 antibody joined to monomethyl auristatin E. In this report, we described a case of a...
5.
Ohuchi K, Fujimura T, Lyu C, Amagai R, Muto Y, Aiba S
Dermatol Ther
. 2020 Jul;
33(6):e14099.
PMID: 32725764
Mogamulizumab is a humanized anti-C-C chemokine receptor type (CCR)4 antibody that shows cytotoxicity against CCR4+ lymphoma cells via antibody-dependent cell-mediated cytotoxicity in advanced cutaneous T cell lymphoma (CTCL) patients. The...
6.
Fujimura T, Tanita K, Ohuchi K, Sato Y, Lyu C, Kambayashi Y, et al.
Melanoma Res
. 2020 Jul;
30(6):613-618.
PMID: 32658051
Nivolumab plus ipilimumab combined therapy is among the most effective therapies for advanced melanoma. However, this therapy is also associated with a high frequency of immune-related adverse events (irAEs). To...
7.
Lyu C, Fujimura T, Amagai R, Ohuchi K, Sato Y, Tanita K, et al.
J Dermatol Sci
. 2020 Jul;
99(1):65-68.
PMID: 32605834
No abstract available.
8.
Ohuchi K, Fujimura T, Kambayashi Y, Amagai R, Lyu C, Tanita K, et al.
Dermatol Ther
. 2020 May;
33(4):e13487.
PMID: 32362053
Mogamulizumab shows cytotoxicity against CCR4+ lymphoma cells by antibody-dependent cell-mediated cytotoxicity (ADCC) in advanced cutaneous T-cell lymphoma (CTCL) patients. Although mogamulizumab is used as one of the anchor drugs for...
9.
Tanita K, Fujimura T, Sato Y, Lyu C, Kambayashi Y, Ogata D, et al.
Front Oncol
. 2019 Oct;
9:907.
PMID: 31616630
Bexarotene is a third-generation retinoid X receptor-selective retinoid that has been approved for use in the treatment of both early and advanced cutaneous T-cell lymphoma (CTCL). Although bexarotene has been...
10.
Fujimura T, Okabe T, Tanita K, Sato Y, Lyu C, Kambayashi Y, et al.
Exp Dermatol
. 2019 Jul;
28(9):1029-1035.
PMID: 31264287
The skin surface temperature reflects the physiological state of the human body. Quantitative methods of identification of skin cancers based on accurate measurement of effective thermal conductivity (ETC) are among...